News

Kymera Therapeutics Announces Pricing of $250 Million Public Offering
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the ...
Zacks Investment Research on MSN1d
KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update
Kymera Therapeutics, Inc. KYMR has announced that partner Sanofi SNY will not advance the development of lead IRAK4 degrader ...
PMLive1d
Gilead Sciences and Kymera enter oncology partnership worth up to $750m
Gilead Sciences and Kymera Therapeutics have entered into a partnership worth as much as $750m to develop a molecular glue ...
PharmExec2d
Gilead, Kymera Launch Collaboration on Novel Oral CDK2 Degraders for Solid Tumors
Under terms of the deal, Kymera will lead early research on novel oral CDK2 degraders for solid tumors, with Gilead assuming ...
Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies
Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.
Kymera: Sanofi Ends KT-474 Work, Will Advance KT-485
Kymera on Wednesday said Sanofi won't advance KT-474, which in late 2023 entered Phase 2 studies trials in patients with the inflammatory skin diseases hidradenitis suppurativa and atopic dermatitis.
Seeking Alpha2d
KYMR Kymera Therapeutics, Inc. - Seeking Alpha
A high-level overview of Kymera Therapeutics, Inc. (KYMR) stock. View (KYMR) real-time stock price, chart, news, analysis, analyst reviews and more.